SFG
CRSP icon

Steward Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Steward Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-165
Closed -$6K – 763
2022
Q4 		$6K Buy
+165
New +$8.75K ﹤0.01% 176
2022
Q3 		– Sell
-165
Closed -$10K – 364
2022
Q2 		$10K Hold
165
– – 0.01% 236
2022
Q1 		$10K Hold
165
– – 0.01% 209
2021
Q4 		$12K Buy
+165
New +$14.4K 0.01% 144

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Steward Financial Group's CRSP Position: Q1 2023 in Review

Steward Financial Group sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 165 shares — an estimated $6K sold.

Steward Financial Group first reported a position in CRSP in Q4 2021 and held it in 4 quarters. The position peaked at $12K in Q4 2021. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

  • Steward Financial Group reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Steward Financial Group sold 165 CRISPR Therapeutics shares in Q1 2023, an estimated $6K.
  • Steward Financial Group first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 4 quarters.
  • Steward Financial Group's CRISPR Therapeutics position peaked at $12K in Q4 2021.
  • 381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Steward Financial Group's 13F filing for Q1 2023, filed 5 May 2023.